Regeneron and Inovio enter trial collaboration for glioblastoma therapy
Regeneron Pharmaceuticals Inc. and Inovio Pharmaceuticals Inc. entered into a trial collaboration to study a combination of their therapies (Regeneron’s REGN2810 with Inovio’s INO5401 and INO9012) to treat patients with newly diagnosed glioblastoma multiforme.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com